L. Becker Hewes
CIK 1840110 · Chief Medical Officer · last filed 2026-01-07
L. Becker Hewes is a Chief Medical Officer who has filed 25 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for GLTO, was dated Jan 7, 2026. Across all open-market trades the lifetime net is −$7.7M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BPMC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CORPORATION
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (GLTO) Delisted | Chief Medical Officer | 264,629 | $28.69 | $7.59M | $0 | 1 | 2026-01-07 |
| Blueprint Medicines Corp (BPMC) Delisted | Chief Medical Officer | 1,607 | $129.46 | $208.0K | -$7.70M | 20 | 2025-07-21 |
Recent Filings
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-07 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | +264,629 | $0 | EDGAR |
| 2025-07-21 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −30,419 | $0 | EDGAR |
| 2025-03-07 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −10,095 | -$890.6K | EDGAR |
| 2025-03-06 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −5,232 | -$458.8K | EDGAR |
| 2025-03-04 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +11,000 | $0 | EDGAR |
| 2024-06-06 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −2,424 | -$254.3K | EDGAR |
| 2024-06-04 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −2,424 | -$254.3K | EDGAR |
| 2024-06-04 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −14,343 | -$2.67M | EDGAR |
| 2024-06-03 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −2,971 | -$316.2K | EDGAR |
| 2024-05-31 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −34,108 | -$3.61M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.